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Histone deacetylase inhibitors (HDACIs) have shown promising anti-tumor effects for a variety of malignancies, however, many
tumors are reportedly resistant to them. In this study, we made a novel discovery that co-administration of HDACIs (Trichostatin
A(TSA)andothers)andexogenouscell-permeableshort-chainceramide(C6)resultsinstrikingincreaseincancercelldeathand
apoptosis in multiple cancer cells. These events are associated with perturbations in diverse cell signaling pathways, including
inactivation of Akt/mTOR and increase in a-tubulin acetylation (both in vivo and in vitro). TSA interacts in a highly synergistic
manner with C6-ceramide to disrupt HDAC6/protein phosphatase 1 (PP1)/tubulin complex, to induce a-tubulin hyperacetylation,
and to release and activate PP1, which then leads to AKT dephosphorylation and eventually causes cancer cell death.
Interestingly, TSA itself results in short-term ceramide accumulation, which as a result of metabolic (glycosylation) removal,
does not result in evident increase of cancer cell death. However, adding C6-ceramide led to a very pronounced increase
in ceramide level and marked increase in cell death. Importantly, the effective synergistic anti-tumor activity of TSA plus
C6-ceramide is also seen in in vivo mice xenograft pancreatic and ovarian cancer models, indicating that this regimen
(HDACI plus C6-ceramide) may represent a more effective form of therapy against pancreatic and ovarian carcinoma.
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In recent years, the importance of epigenetics in cancer
development has been appreciated.
1 Changes in DNA
methylation and histone acetylation have been linked to
aberrant silencing of multiple tumor suppressor genes from a
wide variety of tumors.
2 An array of drugs with histone
deacetylase inhibitors (HDACIs) effect has been described
and many are currently under clinical trials; some HDACIs
have been approved by the USA FDA, for example, vorinostat
(also known as suberoylanilide hydroxamic acid (SAHA)), has
been approved for treatment of T-cell lymphoma.
3 Although
these investigations are actively recruiting patients, to date
these agents are well tolerated and efﬁcacious.
4 The anti-
tumor effects of these drugs are thought to result from
hyperacetylation of histones, demethylation of genomic DNA
and a resulting reactivation of genes that inhibit prolifera-
tion.
5,6 In addition to these transcriptional effects, inhibitors
of deacetylase have also been shown to have signiﬁcant
post-translational effects on non-histone proteins, including
tubulin.
7 Treatment with TSA and other HDACIs cause tubulin
acetylation and stabilization, which then lead to tumor cell
death.
8 Furthermore, recent studies also indicate that TSA
blocks speciﬁc interactions of protein phosphatase 1 (PP1)
with HDAC6, resulting in increased PP1–Akt association,
causing AKT dephosphorylation and inhibition.
8
Membrane sphingolipids are biologically active and have
numerous regulatory effects on cell function, including cell
apoptosis, growth and differentiation.
9,10 Ceramides are a
family of lipid molecules, which is composed of sphingosine
and a fatty acid. Besides its role as a structural element,
ceramides are reported to have strong relationship with apop-
tosis in tumor cells.
11 It has been suggested that processes
that would enhance intracellular ceramide accumulation
would provide favorable proapoptotic outcomes in cancer
chemotherapy.
12 C6-ceramide, a cell-permeable ceramide,
Received 02.9.10; revised 10.12.10; accepted 13.12.10; Edited by A Stephanou
1Department of Physiology, China Pharmaceutical University, Nanjing, PR China;
2Department of Urology, Jiangsu Province Hospital of TCM, Nanjing, PR China;
3Department of Dermatology, the First Afﬁliated Hospital of Nanjing Medical University, Nanjing, PR China;
4Department of Otorhinolaryngology, the First Afﬁliated
Hospital of Nanjing Medical University, Nanjing, PR China;
5Department of Dermatology, the Afﬁliated BenQ Hospital of Nanjing Medical University, Nanjing, PR China
and
6Jiangsu Province Key Lab of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, PR China
*Corresponding author: Y Yang, Department of Physiology, China Pharmaceutical University, Nanjing 210009, PR China. Tel: þ86 25 83271132; Fax: þ86 025
83271132;E-mail: valianty@hotmail.com or GHu,Jiangsu Province Key LabofNeurodegeneration, Department ofPharmacology, Nanjing Medical University,Nanjing,
PR China. Tel: þ86 25 86863108; Fax: þ86 25 86863108; E-mail: ghu@njmu.edu.cn or Z-g Bi, Department of Dermatology, the Afﬁliated BenQ Hospital of Nanjing
Medical University, Nanjing 210019, PR China. Tel: þ86 25 52238800; E-mail: eltonbibenqhospital@yahoo.com.cn
7These authors contributed equally to this work.
Keywords: Trichostatin A; histone deacetylase inhibitors; C6-ceramide; PP1; AKT; Tubulin
Abbreviations: PDMP, 1-phenyl-2-decanoylamino-3-morpholino-1-propanol; CAPP, ceramide-activated protein phosphatase; HDACIs, Histone deacetylase
inhibitors; MAP, microtubule-associated protein; PP1, Protein Phosphatase 1; SAHA, suberoylanilide hydroxamic acid; SB, sodium butyrate; TSA, Trichostatin A
Citation: Cell Death and Disease (2011) 2, e117; doi:10.1038/cddis.2010.96
& 2011 Macmillan Publishers Limited All rights reserved 2041-4889/11
www.nature.com/cddishas shown activity against a variety of cancer cell lines.
13,14
Recent but limited studies have indicated the potential
use of ceramides as an adjuvant for traditional chemo-
therapeutic drugs, such as Taxol, to enhance anti-tumor
effects,
15,16 however, the exact mechanism remains unclear.
In this study, we examined the potential effect of C6-ceramide
to augment the anti-tumor effect of TSA in vitro and in vivo.
TheresultsindicatethatTSA/C6-ceramidecombinationexerted
strongsynergisticeffectsonAKTinhibitionanda-tubulinhyper-
acetylation, which may be the key mechanism to cause cancer
cell death and apoptosis.
Results
In vitro synergism of C6-ceramide and TSA in cancer
cells death. We ﬁrst examined the synergism between
TSA and C6-ceramide in killing cancer cells in ovarian cancer
cell line CaOV3 cells and pancreatic cancer cell line
L3.6 cells in vitro by using 3-[4,5-dimethylthylthiazol-2-yl]-
2,5 diphenyltetrazolium bromide (MTT) assay. C6-ceramide,
which alone had almost no effect on cancer cell death,
markedly enhanced TSA-induced cell death in a dose-
dependent manner in both CaOV3 (Figures 1a and b) and
L3.6 (Figure 1c and d) cells. As shown in Table 1, 100ng/ml
of TSA alone kills almost 8.4% CaOV3 after 48h. In the
presence of 10mg/ml of C6-ceramide (C6-ceramide alone
killed 12.9% CaOV3) however, the same dose of TSA killed
68.3% of CaOV3 cells (Table 1). In CaOV3 cells, TSA’s IC50
(the dose that kills 50% of cancer cells) is 414.3ng/ml,
however, in the presence of C6-ceramide (10mg/ml), its IC50
dropped to 51.2ng/ml (Table 1). Similar results were also
seen in other cancer cells (Table 1). Notably, when cells
are cultured in 10% FBS, either C6-ceramide or TSA alone
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Figure 1 Invitro synergismofTSA/C6-ceramide incancercellsdeath.CaOV3ovariancancercell(a)andL3.6pancreaticcancercell(c)weretreatedwith differentdoses
of TSA (0, 50, 100, 200 and 500ng/ml) in the presence or absence of C6-ceramide (10mg/ml) for 48h, cell viability was detected by MTT assay as described, both cells were
culturedinbasicDMEMmedium.CaOV3(b)andL3.6cells(d)weretreatedwithvaryingdosesofC6-ceramide(0,2.5,5,10,20,40and60mg/ml)inthepresenceorabsence
of TSA (100ng/ml) for 48h, cell viability was detected by MTT assay, both cells were cultured in basic DMEM medium. CaOV3 (e) and L3.6 cells (f), both maintained in 10%
FBSinDMEM,weretreatedwithcombinationofdifferentdoseof TSAandC6-ceramide, cellviabilitywas detectedbyMTTassay.CaOV3(g)orL3.6cells(h)was exposedto
HDACIs sodium butyrate (SB, 1mM) or suberoylanilide hydroxamic acid (SAHA, 1.5mM), in the presence or absence of C6-ceramide (10mg/ml) for 48h, after which the cell
viability was determined by MTT assay. Data are presented as the means±S.D. for three independent experiments. Experiments in this ﬁgure were repeated at least three
times and similar results were obtained. *Po0.05 versus same dose of TSA group without C6-ceramide treatment (ANOVA).
#Po0.05 versus same dose of C6-ceramide
group without TSA treatment (ANOVA)
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Cell Death and Diseasehad very moderate effects on tumor cell death even at a
high dose, however, combination treatment strongly induced
CaOV3 and L3.6 cancer cell death (Figures 1e and f). In vitro
synergism of TSA/C6-ceramide in cancer cell death was
also seen in SKOV3 ovarian cancer cells (Supplementary
Figures S1A and B) and WM-115 melanoma cells
(Supplementary Figures S1C and D). The morphology
pictures in Supplementary Figures S2A and S2B conﬁrmed
the synergistic effects of TSA/C6-ceramide on killing cancer
cells. L3.6 cells cultured in 10% FBS, treated with either
TSA or C6-ceramide alone, had almost no effect on cancer
cell death, whereas concurrent applications largely induced
cell death (Supplementary Figure S2B). Additionally, the
chemosensitization effects of C6-ceramide on other HDACIs-
induced-cancer cell death were also analyzed. As shown
in Figures 1g and h, C6-ceramide markedly enhanced
sodium butyrate (SB) and SAHA, the other two well-
characterized HDACIs-induced cancer cell death in both
CaOV3 and L3.6 cells, indicating that the chemosensitiza-
tion effects of C6-ceramide on HDACIs-induced cancer
cell death is not limited to TSA. Interestingly, although
100ng/ml of TSA caused a signiﬁcant inhibition of cell
proliferation in human hepatoma cell lines HepG2 and
Huh-7,
17 same concentration of TSA had almost no effect
on cell proliferation in CaOV3 and L3.6 cells (Supplementary
Figures S2C, D and E).
In vitro synergism of TSA/C6-ceramide in cancer cell
apoptosis. We next examined the synergism between TSA
and C6-ceramide in inducing cancer cell apoptosis in
different cancer cell lines in vitro via varying methods,
including TUNEL staining (Figure 2a), Hoechst 33342 assay
(Figures 2b and c) and Histone-DNA ELISA assay
(Figure 2d). Results show that, although C6-ceramide
(10mg/ml) or TSA alone had minor effect on cancer cell
apoptosis, a combination of these two caused a marked
increase in cancer cell apoptosis in CaOV3 (Figures 2a–d),
L3.6 (Supplementary Figures S3A and S3B) and SKOV3
cells (Supplementary Figures S3C and S3D). Furthermore,
the expression level of proapoptosis proteins, including Bax,
cleaved-caspase 3 and -9, was also markedly increased
after TSA/C6-ceramide treatment (Figure 2e and Supple-
mentary Figure S4A). Importantly, a combination of C6-
ceramide and TSA-induced cancer cell apoptosis was largely
inhibited by caspase inhibitors Z-DEVDfmk (mainly against
caspase-3) and Z-LEHDfmk (mainly against caspase-9) in
CaOV3 (Figures 2f and g) and L3.6 cells (Supplementary
Figure S4B), indicating that a combination of TSA with
C6-ceramide induced a marked increase in cancer cell
apoptosis in vitro. C6-ceramide also markedly increased
other HDACIs, including SB and SAHA-induced cancer
cell apoptosis, as evidenced by Histone-DNA ELISA assay
(Figure 2h).
Endogenous ceramide production is involved in
TSA-induced cancer cell death. We have shown clearly
that exogenous C6-ceramide markedly enhanced TSA- and
other HDACIs (SB and SAHA)-induced cancer cell death and
apoptosis (Figures 1, 2 and Supplementary Figures S1–S4),
we then tested the possible effects of TSA on endogenous
ceramide production and the effects of endogenous cera-
mide on TSA-induced cancer cell death. Here we found
that minimally toxic concentration of TSA (200 ng/ml) admini-
stration led to an early increase (12 hours) of endogenous
ceramide production in both types of cells. The ability of the
acid sphingomyelinase inhibitor desipramine
18,19 to diminish
TSA-mediated ceramide production (Figures 3a and d) and
cancer cell death/apoptosis (Figures 3b, c, e and f) indicates
that the toxicity of TSA involves activation of acidic sphingo-
myelinase and enhanced endogenous ceramide production.
Interestingly, after a longer time period (48h), the intra-
cellular ceramide level normalizes, suggesting that cancer
cells may be capable of removing excess ceramide through
diverse metabolic pathways.
20,21 Out of different cellular
ceramide metabolic pathways, ceramide glycosylation is of
great importance
22,23 and might facilitate in endogenous
ceramide removal from cancer cells after TSA treatment.
To address this hypothesis, glycosphingolipid biosynthesis
inhibitor 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
(PDMP) was used.
24,25 We ﬁnd that PDMP pretreatment
increased TSA-induced ceramide production and cancer cell
death/apoptosis (Figure 3). On the basis of above-mentioned
information, we proposed that TSA treatment results in short-
term intracellular ceramide accumulation (12h), which, as a
result of metabolic (glycosylation) removal, does not result in
evident increase of cancer cell death. However, co-treatment
with the ceramide glycosylation inhibitor PDMP or by directly
adding exogenous cell-permeable C6-ceramide leads to a
very pronounced increase in ceramide levels and marked
increase in cell death (Figures 1 and 2).
PI3K/AKT inhibition sensitizes cancer cell to TSA-induced
cell death/apoptosis in vitro. We then examined whether
PI3K/AKT inhibition affected TSA-induced cancer cell death
Table 1 C6-ceramide enhances TSA-induced cancer cell death
Cell death after indicated treatments (versus control) IC50 of TSA
Cell lines TSA (100ng/ml) (%) C6 (10lg/ml) (%) TSA+C6 (%) Without C6 (in ng/ml) With C6 (10lg/ml)
CaOV3 8.4±3.5 12.9±5.1 68.3±7.5 414.3 51.2ng/ml
L3.6 23.8±1.1 10.9±3.4 70.1±1.4 314.2 57.8ng/ml
SKOV3 22.5±2.8 14.2±1.5 63.2±2.2 354.2 63.7ng/ml
WM-115 23.5±3.7 12.9±3.0 61.3±6.2 387.9 59.9ng/ml
Cancer cell lines CaOV3, L3.6, SKOV3 and WM-115 were treated with TSA (100ng/ml) with or without C6-ceramide (10mg/ml), cell viability was detected by MTT
assay as shown in Figure 1, percentage of cancer cell death was calculated by reduced MTT value after treatment divided by to control MTT value. IC50 values were
calculated using SPSS statistics 17.0 software (Chicago, IL, USA).
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Cell Death and Diseasein vitro. First, shRNAs speciﬁc to AKT1 and AKT2 were used
to generate AKT1/2 double-knockdown stable L3.6 cancer
cells (Figure 4a). AKT1/2 shRNA-knockdown stable cells
were highly sensitive to TSA compared with control shRNA-
treated cells (Figure 4b). Further, AKT inhibitor X (AKTi),
a commercial available speciﬁc inhibitor of AKT, largely
enhanced TSA-induced cell death in L3.6 cells (Figures 4c
and d). AKT1/2-knockout mouse embryonic ﬁbroblasts
(MEFs) (Supplementary Figure S5) were highly sensitive to
TSA-induced cell death (Figure 4e) and apoptosis (Figure 4f).
These results indicate that PI3K/AKT activation is a major
factor contributing to TSA resistance.
In vitro synergism of TSA/C6-ceramide in AKT/mTOR
inhibition. As we have clearly shown the in vitro synergism
between TSA and C6-ceramide in inducing cancer cell death/
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Cell Death and Diseaseapoptosis (Figures 1 and 2) and AKT activation serves as a
major resistant factor against TSA-induced cell death
(Figure 4), we next tested the possible effects of TSA plus
C6-ceramide on AKT and downstream mTOR activation.
C6-ceramide or TSA alone had moderate effect on
AKT/mTOR inhibition, whereas a combination of these two
drugs induced a large inhibition of AKT/mTOR activation in
both cells (Figures 5a and b, Supplementary Figure S6).
Previous studies have shown that C6-ceramide activates
PP1, a serine/threonine phosphatase, which is involved in
AKT dephosphorylation and inhibition.
26–28 Interestingly, recent
studies also indicated that TSA and other HDACIs induce
PP1 association with AKT, leading to AKT dephos-
phorylation.
8 Here, we conﬁrmed that either C6-ceramide
or TSA alone induced moderate association between PP1
and AKT, whereas a combination of these two drugs leads to
their marked increase in association in both CaOV3
(Figure 5c) and L3.6 cells (Figure 5d), as evidenced by
coimmunoprecipitation assay. It might be the key mechanism
to explain the synergism between TSA and C6-ceramide
in causing AKT/mTOR inhibition. As previous studies
have established that C6-ceramide activates two important
phosphatases PP1
29 and 2A class of serine/threonine
phosphatases (PP2A),
26–28 we next tested the relative
contribution of these two on TSA/C6-ceramide-mediated
AKT inhibition. As shown in Figures 5e and f, PP1-speciﬁc
inhibitor PP1 i2 but not PP2A-speciﬁc inhibitor Cantharidin
reversed TSA/C6-ceramide-induced AKT inhibition, indi-
cating that PP1 rather than PP2A mediates AKT inhibition
by TSA/C6-ceramide treatment. Importantly, as shown in
Figures 5g and h, a combination of these two drugs led to
a marked increase of PP1 activity compared with either
C6-ceramide or TSA treatment alone in both cell types
(Figures 5g and h). Additionally, TSA had almost no effect
on PP2A activity either alone or with C6-ceramide (Data
not shown). To further conﬁrm the requirements of PP1/
HDAC6 in TSA- and C6-ceramide-induced AKT inhibition,
speciﬁc siRNA knockdown were used. As shown in
Figures 5i and j, although knockdown of either PP1 or
HDAC6 alone partially inhibited TSA/C6-ceramide induced
AKT inhibition, knockdown of both proteins almost
completely blocked its effects (Figure 5k). To further
conﬁrm the requirement of PP1 in the deactivation
of AKT by TSA/C6-ceramide, a loss-of-function dominant-
negative myc-D95N PP1 was used. As shown in Figure 5l,
TSA plus C6-ceramide-induced AKT/mTOR inhibition was
reduced in myc-PP1 mutant L3.6 cells. On the basis of this
information, we suggested that combined treatment of TSA/
C6-ceramide synergistically disrupts HDAC6/PP1/tubulin
complex, leading to the release of PP1, which is then
activated by C6-ceramide. Activated PP1 then associates
with AKT, resulting in AKT dephosphorylation and inhibition,
which might be the key mechanism of synergism between
C6-ceramide and TSA.
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Cell Death and DiseaseIn vitro synergism of TSA/C6-ceramide in a-tubulin
acetylation in cancer cell lines. Previous studies have
shown that TSA disrupts HDAC6/a-tubulin complex, causing
a-tubulin acetylation and microtubulin stabilization.
30
Compared with controls, thicker and denser microtubule
bundles were evident in TSA-treated cells, which contributes
to cancer cell apoptosis.
30 We tested the possible effects
of TSA/C6-ceramide on tubulin acetylation. As shown in
Figures 6a and b, although C6-ceramide or TSA alone
had moderate effect in a-tubulin acetylation, a combination
of these two drugs induced a large enhancement of
a-tubulin acetylation in both cells. Furthermore, combination
treatment induced strong disruption of HDAC6/a-tubulin
complex, which might lead to a-tubulin acetylation in both
cells (Figures 6c–f). a-Tubulin acetylation is one of the
consequences of microtubule stability, resulting in cell
cycle arrest and apoptosis.
30–32 Speciﬁc siRNA-knockdown
cells were used to conﬁrm the requirements of PP1/HDAC6
in TSA- and C6-ceramide-induced a-tubulin acetylation.
HDAC6 silencing, which produced an increase in tubulin
acetylation at basic level (non-treatment) inhibited TSA plus
C6-ceramide-induced enhancement of tubulin acetylation
(Figure 6g), PP1 siRNA also inhibited, in relatively lower
level, TSA plus C6-ceramide-induced a-tubulin acetylation
(Figure 6h). Knockdown of both proteins almost reversed
the effects (Figure 6i). On the basis of above-mentioned
information, we propose that C6-ceramide and TSA syner-
gistically cause the disruption HDAC6/a-tubulin complex,
leading to a-tubulin hyperacetylation and eventually cancer
cell death, another potentially important mechanism to
explain the synergism.
C6-ceramide enhances the anti-tumoral efﬁcacy of TSA
in vivo. Two human tumor mice xenograft models were
used for testing the efﬁcacy of the combination treatment.
In both L3.6 and CaOV3 tumor models, the groups that
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Figure 5 In vitro synergism of TSA/C6-ceramide in AKT/mTOR inhibition. CaOV3 or L3.6 cells were either left untreated or treated with indicated treatment (100ng/ml of
TSA, 10mg/ml of C6-ceramide and TSA plus C6-ceramide) for 12h; AKT and downstream mTOR activation were detected by western blot assay by using commercially
available antibodies (a and b). CaOV3 or L3.6 cells were either left untreated or treated with indicated treatment (100ng/ml of TSA, 10mg/ml of C6-ceramide and TSA plus
C6-ceramide)for 2h, the association between PP1/HDAC6/AKT1 were detected byimmunoprecipitation (IP) assay asdescribed (c and d).CaOV3 or L3.6 cells were pretreated
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TSA plus C6-ceramide) for 2h, PP1 activity was detected as described (g and h). L3.6 cells were transfected with control siRNA (scramble, 250nM), PP1 siRNA (250nM),
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transfected with empty vectoror Myc-D95N-PP1 plasmids(1mg/well,describedin materialsand methods)weretreatedwith TSA(100ng/ml) plus C6-ceramide (10mg/ml) for
24h and AKT/mTOR activation was detected using speciﬁc antibodies. Data are presented as the mean±S.D. for three independent experiments. *Po0.05 versus that
indicated in the ﬁgure (ANOVA). All experiments were repeated at least three times and similar results were obtained
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Cell Death and Diseasereceived treatment with either TSA or C6-ceramide as single
agents showed moderately inhibited tumor growth, whereas
the group that received concurrent treatment showed a great
inhibition in tumor growth (enhanced survival rate and
reduced tumor size) (Figures 7a–d). We wondered whether
the in vivo synergism between TSA and C6-ceramide might
be in part related to their effects on tubulin acetylation and
AKT inhibition, as observed in our in vitro studies. Western
blot analysis was performed on total proteins extracted from
the tumor tissues of mouse xenografts treated with solvent,
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Figure 6 In vitro synergism of TSA/C6-ceramide in a-tubulin acetylation in cancer cell lines. CaOV3 or L3.6 cells were either left untreated or treated with indicated
treatment (100ng/ml of TSA, 10mg/ml of C6-ceramide and TSA plus C6-ceramide) for 4h, a-tubulin acetylation were detected by western blot assay by using commercially
available antibodies (a and b). CaOV3 or L3.6 cells were either left untreated or treated as indicated(100ng/ml of TSA, 10mg/ml of C6-ceramide and TSA plus C6-ceramide)
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Cell Death and DiseaseTSA, C6-ceramide, or TSA and C6-ceramide. Although
single-agent treatment with either TSA or C6-ceramide
alone had moderate effect on tubulin acetylation or AKT
inhibition, combined treatment led to a marked increase
in tubulin acetylation and a decrease in AKT activation
(Figures 7e and f). The effect of different treatments (control,
TSA, C6-ceramide, TSA plus C6-ceramide) on body weight
of mice in the xenograft models were demonstrated in
Figures 6g and h. These results are consistent with our
in vitro experiments and suggest that tubulin acetylation/
microtubule stabilization and AKT inhibition might have an
important role in the effectiveness of the TSA/C6-ceramide
combination.
Discussion
In this study, we deﬁned the anti-tumor activity of TSA
and other HDACIs (SB and SAHA) in combination with
C6-ceramide in CaOV3 and L3.6 cancer cells both in vitro and
in vivo. Moderate cancer death and apoptosis were seen
in CaOV3 cells and L3.6 cells, following treatment with
C6-ceramide or TSA (and other HDACIs) alone, whereas
simultaneous treatment with TSA/HDACIs and C6-ceramide
caused synergistic effects, and a marked increase in cancer
cell death and apoptosis (Figures 1 and 2). We provided
evidence to support that treatment with TSA resulted in an
early ceramide accumulation (12h), which, as a result of
metabolic (glycosylation) removal, might not result in a big
increase of cancer cell death. However, co-treatment with the
ceramide glycosylation inhibitor or directly adding exogenous
cell-permeable C6-ceramide led to a very pronounced
increase in ceramide levels and marked increase in cell death
(Figure 3). We suggested that agents that interfere with
ceramide metabolic pathways (for example, PDMP) might
sensitize cancer cells to TSA and possibly other HDACIs-
induced cancer cell death. Activation of AKT is a major factor
contributing to resistance against TSA-induced cancer cell
death, whereas AKT inhibition sensitized cancer cells to
TSA-induced cell death/apoptosis (Figure 4). We provide
evidence to support the model that combined treatment
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Figure 7 C6-ceramide enhances the anti-tumoral efﬁcacy of TSA in vivo. Mice survival and tumor growth were compared with L3.6 (n¼10/group) (a and c) and CaOV3
(n¼10/group) models (b and d). In both models, only groups that received both TSA plus C6-ceramide treatment showed signiﬁcantly smaller tumor volumes and enhanced
mice survival as compared with the mock treatment (control) group, and the group that received single treatment (TSA or C6-ceramide) showed very limited effect in tumor
volume/mice survival. AKT activation and tubulin acetylation were analyzed. In both models, at 4 weeks after drug treatment (mock, TSA, C6-ceramide, combination), tumor
xenograftwerefreshlyremoved,solubilizedandlysedusinglysisbuffer,followedbywesternblotdetectingAKTphosphorylationandtubulinacetylation(eandf).Theeffectsof
different treatments (mock, TSA, C6-ceramide, C6-ceramide plus TSA) on body weight of mice in the xenograft models were demonstrated in g (L3.6 cell model) and h
(CaOV3 model). All experiments were repeated at least three times and similar results were obtained
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Cell Death and Diseasewith TSA/C6-ceramide synergistically disrupts HDAC6/PP1/
tubulin complex, leading to the release of PP1, which is then
activated by C6-ceramide. Subsequently, activated PP1 then
associates with AKT, leading to AKT dephosphorylation and
inhibition (Figure 5). C6-ceramide and TSA synergistically
cause the disruption HDAC6/a-tubulin complex, leading to
a-tubulin hyperacetylation and eventually cancer cell death
(Figure 6). Importantly, the anti-tumor activity of TSA in
combinationwithC6-ceramidewasalsoseenininvivohuman
tumor mice xenograft models. The groups that received
treatment with either TSA or C6-ceramide, as single agents,
showed moderate inhibition of tumor growth, whereas the
group that received the concurrent treatment showed a
signiﬁcant inhibition in tumor growth (Figure 7). In conclusion,
we discovered the synergistic anti-tumor effects of TSA plus
C6-ceramide, both in vitro and in vivo.
Recent studies have indicated the relationship between
TSA and AKT dephosphorylation/inhibition. Those studies
conﬁrmed the existence of cellular HDACs (1 and 6) PP1
complex, and showed that this complex was disrupted by the
treatment of cells with TSA. This caused the release of PP1
from the nuclear PP1/HDACs complex and accounted for the
dephosphorylation of AKT,
8,33 which serves as an important
mechanism to explain the anti-tumor effects of TSA. Here,
we suggest that released PP1 is further activated by
C6-ceramide, which causes further AKT dephosphorylation
and inhibition (Figure 5). Several candidate ceramide-regulated
enzymes, including ceramide-activated protein phosphatase
(CAPP) have been identiﬁed. CAPP was identiﬁed as a
member of the PP2A
26–28 and PP1.
29 Now, it is well
established that short-chain ceramide including C6-ceramide
activates PP1 and PP2A. The speciﬁcity for CAPP activation
in vitro closely resembled the speciﬁcity for various cellular
activities of ceramide.
29 PP1 and PP2A comprises more than
90% of serine/threonine phosphatase activity in mammalian
cells. Both PP1 and PP2A can be activated by C6-ceramide;
here, we found that activation of PP1, but not PP2A, is
important for AKT dephosphorylation by C6-ceramide/TSA
treatment. As PP1 inhibitor, but not PP2A inhibitor, reverses
AKT inhibition by C6-ceramide/TSA treatment, further
C6-ceramide/TSA treatment synergistically enhances PP1
activity, and C6-ceramide/TSA-induced AKT inhibition is
inhibited by PP1 siRNA knockdown and by introducing a
loss-of-function PP1 (dominant negative) to L3.6 cells
(Figure 5).
The HDAC6 catalytic domain binds a- and b-tubulin, two
major components of cytoplasmic microtubules, and cata-
lyzes the deacetylation of a-tubulin.
34–36 Recent studies
observed a small fraction of the total cellular a-tubulin in the
HDAC6/PP1 complex in control cells. Most importantly,
treatment with the broad speciﬁcity HDAC inhibitor TSA
promoted the disassembly of the HDAC6/PP1 complex and
greatly enhanced the acetylation of a-tubulin that was
associated with the remaining PP1 complex.
34–36 Because
a-tubulin acetylation increases following microtubule assem-
bly, it is suggested that PP1 facilitates the recruitment of
HDAC6 to modulate microtubule dynamics. In this regard,
the prevailing evidence implicates HDAC6 in destabilizing
microtubules, whereas inhibition of HDAC6 induces a-tubulin
acetylation and microtubule stabilization. Interestingly, PP1,
which is also recruited to microtubules by the microtubule-
associated protein (MAP) Tau, dephosphorylates Tau and
other MAPs to stabilize microtubules.
37 On the basis of these
results, we suggest that TSA administration disrupts HDACs/
PP1/tubulin complex, leading PP1-bound tubulin acetyla-
tion and stabilization, which is involved in disruption of cell
division and induction of cell apoptosis. Activation of PP1 by
C6-ceramide appears to enhance the acetylation of tubulin,
probably by further disrupting HDAC6/tubulin complex
(Figure 6).
Besidespromotingcancercellapoptosis,anotherimportant
anti-tumor characteristic of ceramide is anti-cancer cell
invasion.
38,39 Interestingly, though the present study convin-
cingly demonstrated that co-administration TSA and exogen-
ous C6-ceramide resulted in a striking increase in cancer cell
apoptosis, previous study has shown that TSA counteracted
C2-ceramide’s (another short-chain ceramide) inhibitory
effects on tumor cell invasion in vitro.
39 This counteraction
effect, resulting from such combination could, however,
affect the effectiveness of current combination approaches
(ceramide plus HDACIs), but more in vivo experiments might
be needed to test this hypothesis. In conclusion, TSA in
combination with C6-ceramide exert synergistic anti-tumor
effects via AKT dephosphorylation (inhibition) and a-tubulin
acetylation, both in vitro and in vivo.
Materials and Methods
Chemicals and reagents. C6-ceramide was purchased from Avanti
(Alabaster, AL, USA AB, CN: 860506P); TSA, AKT inhibitor X (AKTi) and
Rapamycin were purchased from CalbioChem (San Diego, CA, USA). AKT1/2,
Tubulin, HDAC6, PP1, goat anti-rabbit IgG-HRP and goat anti-mouse IgG-HRP
antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
PP2A-speciﬁc inhibitor Cantharidin, PDMP, desipramine, SB, and monoclonal
mouse anti-b-actin were obtained from Sigma (St. Louis, MO, USA). PP1-speciﬁc
inhibitor PP1 I2 was purchased from B&D Bioscience (Franklin Lakes, NJ, USA).
P-AKT (Ser473), p-AKT (Thr308), p-4E-BP1 (Ser65), p-S6 (S235/236), cleaved-
caspase 3 and -9 antibodies were purchased from Cell Signaling Technology
(Beverly, MA, USA). SAHA was purchased from Biomol International (Plymouth
Meeting, PA, USA).
Cell culture. Ovarian cancer cell line CaOV3, SKOV3 cells, pancreatic cancer
cell line L3.6 cells, melanoma cell line WM-115 cells, hepatoma cells HepG2 and
Huh-7(purchased fromShanghai Maisha Biological Technology, Shanghai, China),
AKT wildtype and AKT1/2 double-knockout MEFs were maintained in a DMEM
medium (Sigma), supplemented with a 10% FBS (Invitrogen, Carlsbad, CA, USA),
penicillin/streptomycin (1:100, Sigma) and 4mM L-glutamine (Sigma) in a CO2
incubator at 371C.
Cell viability and the percentage of apoptotic cells assay. Cell
viability was measured by the MTT method. Cells with indicated treatments were
incubated for 20min with 5mg/ml of Hoechst 33342 (Sigma) to stain the nuclei, and
incubated with 2mg/ml of Calcein (CalbioChem, San Diego, CA, USA) to stain the
cytoplasm. After washing with phosphate-buffered saline (PBS), the apoptotic cells
were ﬁxed and observed under a Confocal Fluorescence microscope (Leica TCS
SMD FCS, Leica, Wetzlar, Germany). The Cell Apoptosis ELISA Detection Kit
(Roche, Palo Alto, CA, USA) was used to detect apoptosis in cancer cells with
different treatments. The in situ Cell Death Detection Fluorescein Kit (Roche) was
used to detect apoptosis in cancer cells after indicated treatments according to the
manufacturer’sprotocol.Aftertreatment,theDNAfragmentsfromcellswithdifferent
treatments were stained by TUNEL ﬂuorencein; TUNEL positive-stained cells were
detected using a confocal ﬂuorescence microscope (Leica).
Immunoprecipitation. Cancercellswithindicatedtreatmentswerelysedwith
lysis buffer (200mM NaCl (pH 7.4), 1% Triton X-100, 10% glycerol, 0.3mM EDTA,
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Cell Death and Disease0.2mM Na3VO4 and protease inhibitor cocktails (Roche Diagnostics, Indianapolis,
IN, USA). Aliquots of 800mg of proteins from each sample were precleared by
incubationwith20mlofproteinA/GSepharose(beads)(Amersham,IL,USA)for1h
at 41C. Precleared samples were incubated overnight with speciﬁc antibodies in
lysis buffer at 41C. To this was added 20ml of protein A/G beads and the samples
were incubated for 2h at 41C. The beads were washed ﬁve times with PBS and
once with lysis buffer, boiled, was separated by 10% SDS-PAGE and transferred
onto a PVDF membrane followed by western blotting analysis as described above.
Analysisofintracellularceramidelevels. Thetotalpoolofsphingolipids
was radiolabeled by growing the cells in the presence of 3mCi/ml[
3H]l-serine
(30Ci/mmol; Amersham), a precursor for sphingolipid biosynthesis. After indicated
treatment, the medium was removed and the cells were ﬁxed in ice-cold CH3OH,
followed by lipid extraction from the cells
20. Aliquots of the lipid extracts were taken
for the determination of the total amount of lipid-incorporated radioactivity.
Acylglycerolipidswerehydrolyzedduring1hof incubationat 371C inCHCl3/CH3OH
(1:1,v/v)containing0.1MKOH.Theremaininglipidswerere-extractedandapplied
on high-performance thin-layer chromatography plates. Plates were developed in
CHCl3/CH3OH/H2O (14:6:1, v/v) in ﬁrst dimension and in CHCl3/CH3COOH
(9:1, v/v) in second dimension to resolve ceramide. Ceramide-containing spots
were scraped and subjected to scintillation counting. The effects of TSA and
inhibitors on ceramides levels were determined by growing the cells, after overnight
adherence, for 4 days in medium containing [
3H]serine. Drugs were present for the
last 2-day period or the ﬁnal 12h before the end of incubation. Treatment with
0.1units/ml bacterial sphingomyelinase (Sigma) for the ﬁnal 2h of the incubation
served as positive control (maximal ceramide formation from sphingomyelin; see
ref. 20). Cellular ceramide production was indicated as fold change compared with
untreated control.
Plasmids. To generate myc–PP1 expression vectors, PP1a cDNA was PCR
ampliﬁed using primer pairs 50-GGGCTCGAGGCCACCATGTCCGACAGCGAG
AAGCTC-30and 50-GGGAAGCTTTTTCTTGGCTTTGGCAGAGTT-30, and a rabbit
PP1a cDNA as a template and subclonedinto the XhoI and HindIII sites of pcDNA3
D95N. myc-PP1 mutants were generated using the QuikChange Site-Directed
mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer’s
protocol.
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RNAi and Plasmid transfection. siRNA for PP1, HDAC6 were purchased
from Santa Cruz Biotechnology. L3.6 cells were seeded in a six-well plate one day
before transfection and cultured to 60% conﬂuence the following day in 2% FBS
medium. For RNAi experiments, 4.5ml PLUS reagent (Invitrogen) was diluted in
90ml of RNA dilution water (Invitrogen) for 5min in room temperature. Then, 10ml
PP1/HDAC6 siRNA (25mM) or control siRNA (25mM) was added to PLUS reagent
and left for 5min at room temperature. Lipofectamine (4.5ml) (Invitrogen) was then
added to the complex. After 30min incubation, the transfection complex was
formed. Finally, the complex was added to the wells containing 1ml of medium with
the ﬁnal siRNA concentration of 250nM. PP1/HDAC6 protein expression was
determined by western blot at 72h after transfection, and only successfully
knockdown cells were used for further experiments. For plasmid transfection, 1mg
of plasmid was transfected to each well of one six-well plate using the same
transfection methods mentioned above.
In vivo human tumor mice xenograft model. L3.6 cells were implanted
into the ﬂanks of 6- to 8-week-old nude mice (1 10
6 cells/implantation). Once the
tumor size reached 50–100mm
3, the animals were randomized into four groups
(n¼10/group): PBS, TSA, C6-ceramide and combination. TSA (1mg/kg) was
administered intraperitoneally daily for 12 days (the ﬁrst day of injection counted as
day 0), with or without intraperitoneally injections of C6-ceramide (10mg/kg) were
administered on days 1–6. Tumor volumes and animal survival were monitored two
to three times a week. The animals were killed using procedures that were in
accordance with institutional regulations. A similar experiment was performed
on CaOV3 tumors. Tumor-bearing mice were randomized into four groups
(n¼10/group). TSA was administered as described earlier and intraperitoneal
injections of C6-ceramide were administered on days 1–6. At 4 weeks after
treatmentwithdrug,tumorxenograftswerefreshlyremoved,lysedusinglysisbuffer
described above, followed by western blot detecting AKT phosphorylation and
tubulin acetylation. All animal studies were approved by the institutional review
board of China Pharmaceutical University.
Statisticalanalysis. Thevaluesintheﬁguresareexpressedasmeans±S.D.
The ﬁgures in this study were representatives of more than three different
experiments. Values of Po0.05 were considered as statistically signiﬁcant
(ANOVA) with a Newman–Keuls post test.
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